Annabel Samimy
Stock Analyst at Stifel
(4.30)
# 460
Out of 4,761 analysts
58
Total ratings
44%
Success rate
26.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $23.77 | +110.39% | 1 | Jan 8, 2025 | |
| ALT Altimmune | Initiates: Buy | $18 | $6.43 | +179.94% | 1 | Jan 8, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 → $17 | $2.84 | +498.59% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $10.88 | +267.65% | 1 | Oct 8, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $7.46 | +141.29% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $5.67 | +323.28% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $7.27 | +450.21% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $34.07 | +134.81% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $136.01 | +69.11% | 8 | Mar 15, 2024 | |
| EOLS Evolus | Reiterates: Buy | $23 → $25 | $13.99 | +78.70% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $21.41 | +63.48% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $27.52 | +136.19% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $336 | $4.97 | +6,660.56% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $28 → $11 | $0.71 | +1,458.29% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $9.56 | +370.71% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $0.95 | +742.11% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.66 | +1,345.78% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $20 | $13.17 | +51.86% | 1 | Apr 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.30 | +57,592.31% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $33.05 | -27.38% | 7 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $21 | $0.80 | +2,528.29% | 6 | Sep 18, 2019 |
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $23.77
Upside: +110.39%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $6.43
Upside: +179.94%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $2.84
Upside: +498.59%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $10.88
Upside: +267.65%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.46
Upside: +141.29%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $5.67
Upside: +323.28%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $7.27
Upside: +450.21%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $34.07
Upside: +134.81%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $136.01
Upside: +69.11%
Evolus
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $13.99
Upside: +78.70%
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $21.41
Upside: +63.48%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $27.52
Upside: +136.19%
Jun 27, 2023
Reiterates: Buy
Price Target: $336
Current: $4.97
Upside: +6,660.56%
Jun 26, 2023
Downgrades: Hold
Price Target: $28 → $11
Current: $0.71
Upside: +1,458.29%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $9.56
Upside: +370.71%
Nov 10, 2022
Upgrades: Buy
Price Target: $8
Current: $0.95
Upside: +742.11%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.66
Upside: +1,345.78%
Apr 24, 2020
Initiates: Hold
Price Target: $20
Current: $13.17
Upside: +51.86%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.30
Upside: +57,592.31%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $33.05
Upside: -27.38%
Sep 18, 2019
Maintains: Hold
Price Target: $15 → $21
Current: $0.80
Upside: +2,528.29%